JP2013523843A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013523843A5 JP2013523843A5 JP2013504061A JP2013504061A JP2013523843A5 JP 2013523843 A5 JP2013523843 A5 JP 2013523843A5 JP 2013504061 A JP2013504061 A JP 2013504061A JP 2013504061 A JP2013504061 A JP 2013504061A JP 2013523843 A5 JP2013523843 A5 JP 2013523843A5
- Authority
- JP
- Japan
- Prior art keywords
- vegf
- cancer
- antibody
- drug according
- antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 claims 14
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 claims 14
- 239000003814 drug Substances 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 10
- 229940079593 drug Drugs 0.000 claims 9
- 239000005557 antagonist Substances 0.000 claims 7
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 5
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 claims 3
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 claims 3
- 230000000259 anti-tumor effect Effects 0.000 claims 3
- 239000000890 drug combination Substances 0.000 claims 3
- 210000004408 hybridoma Anatomy 0.000 claims 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 2
- 230000000118 anti-neoplastic effect Effects 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 229960002949 fluorouracil Drugs 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 230000000306 recurrent effect Effects 0.000 claims 2
- 229960004964 temozolomide Drugs 0.000 claims 2
- 108091023037 Aptamer Proteins 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 208000024055 brain glioblastoma Diseases 0.000 claims 1
- 201000011609 brain glioblastoma multiforme Diseases 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- 229940000425 combination drug Drugs 0.000 claims 1
- 239000002131 composite material Substances 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 210000004907 gland Anatomy 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32460810P | 2010-04-15 | 2010-04-15 | |
| US61/324,608 | 2010-04-15 | ||
| PCT/AU2011/000386 WO2011127519A1 (en) | 2010-04-15 | 2011-04-05 | Combination treatment with vegf-c antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015185027A Division JP2016040269A (ja) | 2010-04-15 | 2015-09-18 | Ｖｅｇｆ−ｃ拮抗剤を用いた併用治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013523843A JP2013523843A (ja) | 2013-06-17 |
| JP2013523843A5 true JP2013523843A5 (enExample) | 2014-05-22 |
Family
ID=44798165
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013504061A Pending JP2013523843A (ja) | 2010-04-15 | 2011-04-05 | Ｖｅｇｆ−ｃ拮抗剤を用いた併用治療 |
| JP2015185027A Withdrawn JP2016040269A (ja) | 2010-04-15 | 2015-09-18 | Ｖｅｇｆ−ｃ拮抗剤を用いた併用治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015185027A Withdrawn JP2016040269A (ja) | 2010-04-15 | 2015-09-18 | Ｖｅｇｆ−ｃ拮抗剤を用いた併用治療 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US20120207671A1 (enExample) |
| EP (1) | EP2558122A4 (enExample) |
| JP (2) | JP2013523843A (enExample) |
| CA (1) | CA2796205A1 (enExample) |
| WO (1) | WO2011127519A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2809335A4 (en) * | 2012-02-02 | 2015-10-28 | Acceleron Pharma Inc | ALK1 ANTAGONISTS AND THEIR USE FOR THE TREATMENT OF NIERENZELLENKARZINOMEN |
| US20140057851A1 (en) * | 2012-08-24 | 2014-02-27 | WKD Holding Oy | Anti-Angiogenic Gene Therapy With Soluble VEGF Receptors -1, -2 and -3 Together With Paclitaxel Prolongs Survival Of Mice With Human Ovarian Carcinoma |
| US12024568B2 (en) | 2012-09-13 | 2024-07-02 | Cornell University | Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies |
| US10561707B2 (en) | 2013-09-08 | 2020-02-18 | Technion Research And Development Foundation Ltd. | Semaphorin 3C variants, compositions comprising said variants and methods of use thereof in treating eye diseases |
| KR102131370B1 (ko) | 2013-10-18 | 2020-07-08 | 삼성전자주식회사 | Vegf-c에 특이적으로 결합하는 폴리펩타이드 및 그의 용도 |
| CN116440279A (zh) * | 2015-09-17 | 2023-07-18 | 伊缪诺金公司 | 包含抗folr1免疫缀合物的治疗组合 |
| EP3407846B1 (en) * | 2016-01-25 | 2021-09-22 | Technion Research & Development Foundation Limited | Composition comprising a semaphorin 3c or variant thereof for use in treating age-related macular degeneration |
| EP3272771A1 (en) | 2016-07-22 | 2018-01-24 | Centre National De La Recherche Scientifique | Treatment for use for preventing metastasis in a subject exposed to cancer treatment inducing p38 activation |
| EP3446704A1 (en) | 2017-08-24 | 2019-02-27 | Isofol Medical AB | [6r]-mthf - an efficient folate alternative in 5-fluorouracil based chemotherapy |
| KR20190112711A (ko) | 2017-02-14 | 2019-10-07 | 이소폴 메디컬 에이비 | 혈장 2'-데옥시우리딘 (dUrd) 및 티미딜레이트 신타제 억제를 증가시키는 방법 |
| WO2018189403A1 (en) | 2017-04-14 | 2018-10-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of cancer |
| WO2022238459A1 (en) * | 2021-05-11 | 2022-11-17 | Centre National De La Recherche Scientifique (Cnrs) | New humanized anti-vegfc antibodies and uses thereof |
| JP2024529119A (ja) * | 2021-08-13 | 2024-08-01 | イノベント バイオロジクス（スーチョウ）カンパニー，リミティド | 抗ｖｅｇｆａとｖｅｇｆｃ二重特異性抗体およびその使用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6824777B1 (en) * | 1992-10-09 | 2004-11-30 | Licentia Ltd. | Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy |
| US20050232921A1 (en) * | 2001-04-13 | 2005-10-20 | Rosen Craig A | Vascular endothelial growth factor 2 |
| EP2228389B1 (en) * | 2001-04-13 | 2015-07-08 | Human Genome Sciences, Inc. | Antibodies against vascular endothelial growth factor 2 |
| SI1784426T1 (sl) * | 2004-09-03 | 2012-03-30 | Genentech Inc | Humanizirani antagonisti proti beta in njihove uporabe |
| JP2010507626A (ja) * | 2006-10-27 | 2010-03-11 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｖｅｇｆｒ３阻害剤としての大環状キナゾリン誘導体 |
| US20100029491A1 (en) * | 2008-07-11 | 2010-02-04 | Maike Schmidt | Methods and compositions for diagnostic use for tumor treatment |
| EP2538965B1 (en) * | 2010-02-25 | 2017-04-12 | Schepens Eye Research Institute | Therapeutic compositions for the treatment of dry eye disease |
-
2011
- 2011-04-05 US US13/501,600 patent/US20120207671A1/en not_active Abandoned
- 2011-04-05 EP EP11768266.6A patent/EP2558122A4/en not_active Withdrawn
- 2011-04-05 WO PCT/AU2011/000386 patent/WO2011127519A1/en not_active Ceased
- 2011-04-05 JP JP2013504061A patent/JP2013523843A/ja active Pending
- 2011-04-05 CA CA2796205A patent/CA2796205A1/en not_active Abandoned
-
2013
- 2013-08-29 US US14/013,203 patent/US20130344065A1/en not_active Abandoned
-
2015
- 2015-04-27 US US14/697,175 patent/US20150224191A1/en not_active Abandoned
- 2015-09-18 JP JP2015185027A patent/JP2016040269A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013523843A5 (enExample) | ||
| Walker et al. | Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options? | |
| Fornaro et al. | FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO) | |
| Guo et al. | Interleukin-6 signaling pathway in targeted therapy for cancer | |
| JP2018508512A5 (enExample) | ||
| JP2008531576A5 (enExample) | ||
| RU2020102237A (ru) | Связывающие il-1-бета антитела для применения в лечении рака | |
| JP2011512332A5 (enExample) | ||
| JP2007526455A5 (enExample) | ||
| HRP20220399T1 (hr) | Režim doziranja imunokonjugata protutijela i sn-38 za poboljšanu učinkovitost i smanjenu toksičnost | |
| JP2017533912A5 (enExample) | ||
| JP2017506264A5 (enExample) | ||
| JP2020524694A5 (enExample) | ||
| JP2018536632A5 (ja) | Ｂ７‐ｈ３に特異的に結合する分子及びｐｄ‐１に特異的に結合する分子 | |
| IL276434B1 (en) | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer | |
| ME02470B (me) | Nanočesтice nabijene sa hemoterapeutskim anтitumorskim lekom | |
| JP2015532292A5 (enExample) | ||
| JP2014034576A5 (enExample) | ||
| ME02148B (me) | Notch-vezivni agensi i antagonisti i postupci za njihovo korišćenje | |
| RU2018111529A (ru) | Комбинированная терапия для лечения рака | |
| JP2013520442A5 (enExample) | ||
| RU2015143437A (ru) | Способы лечения рака и предотвращения устойчивости к лекарственным препаратам для лечения рака | |
| JP2021500349A5 (enExample) | ||
| JP2019524701A5 (enExample) | ||
| Vermorken et al. | A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors |